较量ICS剂量减少与蒙特卢卡斯特停药的逐步降低治疗在控制良好的喘:一个试点随机对照试验
Besharat Rahimi1, Niloofar Khoshnam Rad2, Shahideh Amini3
1Thoracic Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
BMC pulmonary medicine
|April 9, 2025
概括
减少吸入性皮质类固醇 (ICS) 剂量可以保持喘控制和降低恶化风险. 这项试点研究发现,当ICS剂量减少时,与停止蒙特卢卡斯特相比,患有控制良好的喘的成年人治疗失败率更低.
科学领域:
- 肺部病理学 肺部病理学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 喘指南建议减少吸入性皮质类固醇 (ICS) 剂量,以控制喘.
- 有限的证据直接支持将ICS剂量降低作为逐步降低策略.
- 这项研究比较了ICS剂量降低与蒙特卢卡斯特停用.
研究的目的:
- 为了比较ICS剂量减少与蒙特卢卡斯特停药的有效性.
- 为了评估成年人患有控制良好的喘的逐步降低策略.
主要方法:
- 一项试点随机对照试验,涉及73名患有控制良好的喘的成年人.
- 参与者被随机分配到ICS剂量减少 (n=37) 或停止蒙特卢卡斯特治疗 (n=36).
- 主要结局是控制喘 (ACT评分);次要结局包括三个月的肺功能和恶化.
主要成果:
- 组之间整体喘控制 (ACT得分) 没有显著差异 (p=0.42).
- 与蒙特卢卡斯特中止相比,ICS剂量降低组的治疗失败明显减少 (p=0.01).
- 没有报告任何严重的不良事件.
结论:
- 减少ICS剂量表明,治疗失败的趋势越来越少.
- 减少ICS剂量可能有助于保持喘控制和减少恶化.
- 需要进行更大规模的长期研究来证实这些发现.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
172
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
172
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
156
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
156
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
182
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
182
Drugs Used in Lower Respiratory Disorders: Overview
278
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
278
COPD: Management Using Bronchodilators and Corticosteroids
144
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
144
Inhaled Medications
205
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
205


